News Drug Development

Basilea Pharmaceutica Reports 2006 Interim Results Reflecting Successful Investment In Late-stage Development Programs

August 24, 2006 |

1 min read

BASEL, Switzerland, Aug. 24, 2006 (PRIMEZONE) -- Basilea Pharmaceutica Ltd. (SWX:BSLN) reports interim financial results. Three compounds planned to be in phase III by year-end.

Clinical research Phase III Earnings Europe

MORE ON THIS TOPIC

Pictured: Boehringer Ingelheim sign on a building/

Schizophrenia

Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS

January 17, 2025

·

2 min read

·

Tristan Manalac

Businessman jump careful on cracked or broken graph. Job opportunity and career. concept of under pressure. risk, financial, and tax

Pipeline

New Safety Signals Force Keros to Fully Terminate Mid-Stage PAH Study

January 15, 2025

·

2 min read

·

Tristan Manalac

Business

Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More

January 15, 2025

·

1 min read

·

Heather McKenzie

Pictured: Aerial view of the San Francisco skyline

Pipeline

JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen

January 15, 2025

·

4 min read

·

Tristan Manalac